# Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

> **NCT04590664** · PHASE1,PHASE2 · RECRUITING · sponsor: **Emory University** · enrollment: 24 (estimated)

## Conditions studied

- Glioblastoma
- Recurrent Glioblastoma

## Interventions

- **DRUG:** Verteporfin

## Key facts

- **NCT ID:** NCT04590664
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-15
- **Primary completion:** 2025-08-15
- **Final completion:** 2025-08-15
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04590664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04590664, "Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04590664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*